[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Dünne AA, Kuropkat C, Sapundzhiev N, Ramaswamy A, Sesterhenn A, Schulz S, Werner JA: Intravenous chemotherapy with cisplatin for regional lymph node metastases of auricular VX2 carcinoma. Anticancer Res; 2004 May-Jun;24(3a):1785-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous chemotherapy with cisplatin for regional lymph node metastases of auricular VX2 carcinoma.
  • INTRODUCTION: The VX2 carcinoma is well established as a useful model for studies on treatment of primary tumors of various locations including the rabbit's auricle; however, limited experience exists on the treatment modalities of lymph node (LN) metastases.
  • In this investigation we studied the frequency and extent of lymphogenic metastatic spread of auricular VX2-carcinomas and their response to systemic chemotherapy.
  • MATERIALS AND METHODS: Induction of a right-sided auricular VX2-carcinoma in 17 healthy New Zealand white rabbits was followed by ablation of the right auricle and intravenous application of 1 mg/kg KG CDDP (cisdiamminedichloroplatinum (II)) dissolved in 2 ml NaCl via the left-sided auricular vein in 10 rabbits (group 1), while 7 rabbits (group 2) remained untreated.
  • Following intravenous cisplatin therapy (ICT), 6/10 animals showed no vital tumor cells within LN metastases of the first draining LN station, while 4/10 animals had necrotic LN metastases limited to the parotideal LN. Group 2.
  • CONCLUSION: The auricular VX2-carcinoma, characterized by frequent lymphogenic metastatic spread and response of LN metastases to ICT, offers an excellent animal model for further studies on the optimised treatment of lymphogenic metastatic spread in HNSCC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cisplatin / pharmacology. Ear Neoplasms / drug therapy
  • [MeSH-minor] Animals. Ear, External / blood supply. Female. Infusions, Intravenous. Lymphatic Metastasis. Rabbits

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15274356.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Fleiner F, Jumah M, Göktas O: Cancer of the external auditory canal-diagnostic and treatment. Indian J Otolaryngol Head Neck Surg; 2009 Dec;61(4):270-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the external auditory canal-diagnostic and treatment.
  • BACKGROUND: Ear squamous cell carcinoma (SCC) is a tumor with a poor prognosis, due to a late initial diagnosis because of a concealment by primarily benign symptoms and due to the unfavorable localization including the infiltration of important structures such as the middle ear, mandibular joint or dura.
  • PATIENTS AND METHODS: We retrospectively examined 10 patients, medium age: 63.8 ± 9.3 years between 2002 and 2008 with a histological confirmed SCC of the external auditory canal.
  • RESULTS: The treatment involving surgery, radiotherapy and/or chemotherapy yielded a survival rate of 38.3 ± 11.3 months for T1 and a survival rate of 17.0 ± 3.0 months for T2-T4 tumors.
  • CONCLUSION: The prognosis for ear SCC primarily depends on early clinical and histopathological diagnostics and requires a sufficient and standardized staging to determine the therapy involving surgery and radiochemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1977 Oct;87(10 Pt 1):1622-34 [904397.001]
  • [Cites] Laryngoscope. 1976 Mar;86(3):405-15 [1256215.001]
  • [Cites] Laryngoscope. 1990 Nov;100(11):1215-8 [2233086.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Sep;99(9 Pt 1):714-21 [2396807.001]
  • [Cites] Am J Otol. 1989 Mar;10(2):111-6 [2735381.001]
  • [Cites] Am J Otol. 1988 Sep;9(5):351-6 [3059809.001]
  • [Cites] Laryngoscope. 1987 Feb;97(2):158-64 [3807618.001]
  • [Cites] J Laryngol Otol. 1985 Sep;99(9):847-50 [4045304.001]
  • [Cites] Am J Otol. 2000 Jul;21(4):582-8 [10912706.001]
  • [Cites] J Laryngol Otol. 2006 Aug;120(8):684-6 [16719955.001]
  • [Cites] Skull Base. 2008 May;18(3):167-72 [18978963.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1984 Oct;9(5):281-99 [6391749.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):687-9 [8499104.001]
  • [Cites] HNO. 2001 Apr;49(4):256-63 [11382105.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):834-7 [12117346.001]
  • [Cites] J Laryngol Otol. 1965 Feb;79:85-119 [14256270.001]
  • (PMID = 23120649.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450079
  • [Keywords] NOTNLM ; Carcinoma of the external auditory canal / Prognosis / Radiation treatment / Squamous cell carcinoma / Surgery
  •  go-up   go-down


3. Ferrandina G, Salutari V, Testa A, Zannoni GF, Petrillo M, Scambia G: Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature. BMC Cancer; 2006;6:169
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature.
  • CASE PRESENTATION: A 38-year old patient, submitted to radical hysterectomy and pelvic lymphadenectomy for a squamous FIGO stage IB1 cervical carcinoma, presented after 76 months with a palpable, and painless swelling on the left hemithorax.
  • Pathology revealed the presence of metastasis of squamous cell carcinoma of similar morphology as the primary.
  • The patient was triaged to chemotherapy plus external radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Muscle Neoplasms / secondary. Muscle, Skeletal. Thoracic Wall. Uterine Cervical Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] Obstet Gynecol. 2001 Oct;98(4):680-4 [11576588.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Dec;14(6):447-8 [12512964.001]
  • [Cites] Cancer Radiother. 2003 Jun;7(3):187-9 [12834775.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • [Cites] Rinsho Hoshasen. 1990 Oct;35(11):1447-50 [2277431.001]
  • [Cites] Singapore Med J. 2003 Jun;44(6):302-3 [14560863.001]
  • [Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):372-6 [8088616.001]
  • [Cites] Ear Nose Throat J. 1995 Feb;74(2):118-21 [7705230.001]
  • [Cites] Isr J Med Sci. 1997 Oct;33(10):674-6 [9397142.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):54-8 [15904950.001]
  • [Cites] Gynecol Oncol. 1991 Jun;41(3):255-8 [1869105.001]
  • (PMID = 16800899.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC1523362
  •  go-up   go-down


Advertisement
4. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS: Locoregional cancer treatment with magnetic drug targeting. Cancer Res; 2000 Dec 1;60(23):6641-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional cancer treatment with magnetic drug targeting.
  • The specific delivery of chemotherapeutic agents to their desired targets with a minimum of systemic side effects is an important, ongoing challenge of chemotherapy.
  • One approach, developed in the past to address this problem, is the i.v. injection of magnetic particles [ferrofluids (FFs)] bound to anticancer agents that are then concentrated in the desired area (e.g., the tumor) by an external magnetic field.
  • In the present study, we treated squamous cell carcinoma in rabbits with FFs bound to mitoxantrone (FF-MTX) that was concentrated with a magnetic field.
  • Experimental VX-2 squamous cell carcinoma was implanted in the median portion of the hind limb of New Zealand White rabbits (n = 26).
  • ; femoral artery) or i.v. (ear vein), whereas an external magnetic field was focused on the tumor.
  • FF-MTX i.a. application with the external magnetic field resulted in a significant (P < 0.05), complete, and permanent remission of the squamous cell carcinoma compared with the control group (no treatment) and the i.v.
  • Thus, our data show that i.a. application of FF-MTX is successful in treating experimental squamous cell carcinoma.
  • This "magnetic drug targeting" offers a unique opportunity to treat malignant tumors locoregionally without systemic toxicity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems. Magnetics. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Colloids / administration & dosage. Colloids / pharmacokinetics. Drug Carriers. Female. Ferric Compounds / administration & dosage. Ferric Compounds / pharmacokinetics. Magnetic Resonance Imaging. Mitoxantrone / administration & dosage. Mitoxantrone / pharmacokinetics. Rabbits

  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11118047.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Colloids; 0 / Drug Carriers; 0 / Ferric Compounds; 1K09F3G675 / ferric oxide; 2UA751211N / ferric hydroxide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


5. Ogawa K, Nakamura K, Hatano K, Uno T, Fuwa N, Itami J, Kojya S, Nakashima T, Shinhama A, Nakagawa T, Toita T, Sakai M, Kodaira T, Suzuki M, Ito H, Murayama S: Treatment and prognosis of squamous cell carcinoma of the external auditory canal and middle ear: a multi-institutional retrospective review of 87 patients. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1326-34
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and prognosis of squamous cell carcinoma of the external auditory canal and middle ear: a multi-institutional retrospective review of 87 patients.
  • PURPOSE: To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear.
  • METHODS AND MATERIALS: The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed.
  • Chemotherapy was administered in 34 patients (39%).
  • On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS.
  • On multivariate analysis, T stage and treatment modality were significant prognostic factors.
  • Chemotherapy did not influence DFS.
  • The 5-year DFS rate in T1, T2, and T3 patients was 83%, 45%, and 0 in the RT group (p < 0.0001) and 75%, 75%, and 46% in the S + RT group (p = 0.13), respectively.
  • CONCLUSIONS: Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease.
  • Further clarification on the role of chemotherapy is necessary.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Ear Canal. Ear Neoplasms / therapy. Ear, Middle

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446002.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


6. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx; 2006 Sep;33(3):251-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 95 cases of squamous cell carcinoma of the external and middle ear.
  • OBJECTIVE: To analyze the clinical characteristics, 5-year survival, and prognostic factors of squamous cell carcinoma (SCC) of the external and middle ear.
  • Ninety five cases of patients from 10 institutions were reviewed on their age and sex distribution, initial complaints, stages, tumor locations, treatments, and outcomes.
  • SCC located in the external ear could be detected in an earlier stage than that in the middle ear.
  • SCC in stages I and II was susceptible to each therapeutic strategy with a 5-year survival of 100%.
  • Operation combined with radiotherapy and/or chemotherapy was the major treatment for stages III and IV SCC, while radiotherapy and chemotherapy were applied mainly for those who had been considered inappropriate for operation.
  • The overall survival was 67.2% for stage III and 29.5% for stage IV, and operation with pathologically tumor free margin could improve the survival to 72.7% when combined with radio- and chemotherapy.
  • CONCLUSION: Local infiltration seems to be the main behavior of SCC in the external and middle ear.
  • Early diagnosis and treatment were important because SCC in the earlier stage is susceptible to be cured.
  • For tumors of advanced stage, operation should be performed with pathologically tumor free margin, and operation combined with radiotherapy and chemotherapy could improve the survival.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Ear Neoplasms / epidemiology. Ear, External. Ear, Middle

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431060.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


7. Palma S, Cavazzini L, Bovo R, Padovani D, Bugli AM, Borrelli M, Martini A: Merkel cell tumour of the external ear. Report of a case. Auris Nasus Larynx; 2007 Jun;34(2):229-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumour of the external ear. Report of a case.
  • Merkel cells carcinoma (MCC) is an uncommon skin lesion, considered a malignancy of the neuroendocrine system, which is found mainly in elderly people.
  • To our best knowledge 20 cases originated from the auricle have been described, 2 of them arising from external ear canal.
  • The authors report a case of the ear canal characterized by two others synchronous tumours and the occurrence of a malignant high grade lymphoma, in which contribute of the pathologist was essential for a critical review.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Ear Neoplasms / diagnosis. Ear, External
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Fatal Outcome. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Humans. Keratins / analysis. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Magnetic Resonance Imaging. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Parotid Gland / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064866.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


8. Liao HT, Chien CH, Chen CH, Wang HP, Huang DF: Recurrent autoimmune inner ear disease (AIED) and polyarteritis nodosa in a patient with large cell lung carcinoma. Clin Rheumatol; 2007 Jun;26(6):1008-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent autoimmune inner ear disease (AIED) and polyarteritis nodosa in a patient with large cell lung carcinoma.
  • Autoimmune inner ear disease (AIED) is a very rare disorder with distinct clinical features and can occur in patients with malignancy or autoimmune diseases.
  • We report a 72-year-old male patient with polyarteritis nodosa treated continuously for 5 years with aggressive immunosuppressive drugs, including cyclophosphamide, who experienced three episodes of acute hearing loss during treatment.
  • Organic lesions of the external and middle ear were excluded by repeated examinations, and if one subscribes to McCabe's (Ann Otol Rhinol Laryngol 88:585-589, 1979) definition of AIED, this condition must be considered as the likely cause of the hearing loss.
  • During the period of treatment, three episodes of AIED occurred, and eventually, lung cancer developed.
  • From the time relationship and clinical manifestations of neuropathy and livedo reticularis, the first episode of hearing loss was more likely to be related to vasculitis itself, while the third episode may well have been associated with the development of lung cancer given the dramatic improvement in the clinical condition following treatment of the tumor by excision and cancer chemotherapy.
  • For those patients with autoimmune disease who are on long-term immunosuppressive drug therapy, active surveillance for a nascent malignant tumor should be exercised if AIED recurs or persists.
  • [MeSH-major] Autoimmune Diseases / complications. Carcinoma, Large Cell / complications. Carcinoma, Non-Small-Cell Lung / complications. Labyrinth Diseases / immunology. Lung Neoplasms / complications. Polyarteritis Nodosa / complications


9. Hiraga S, Miyoshi Y, Kishimoto S: [Successful treatment of multiple pulmonary metastases of adenoid cystic carcinoma of the external auditory meatus with TS-1]. Gan To Kagaku Ryoho; 2004 Jul;31(7):1115-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of multiple pulmonary metastases of adenoid cystic carcinoma of the external auditory meatus with TS-1].
  • The patient, a 67-year old man, was referred to us with refractory otorrhea of the left ear.
  • The diagnosis was adenoid cystic carcinoma of the external auditory meatus, so the primary focus was excised.
  • Thus, it was possible to continue medication for 15 months on an ambulatory basis.
  • It was indicated that TS-1 may be effective in the treatment of multiple pulmonary metastases of adenoid cystic carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / secondary. Ear Canal. Ear Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Humans. Male

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272597.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


10. Ogino S, Iino Y, Nakamoto Y, Murakami Y, Toriyama M: [Histopathological study of the temporal bones in patients with primary carcinomas of the ear]. Nihon Jibiinkoka Gakkai Kaiho; 2000 Oct;103(10):1141-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathological study of the temporal bones in patients with primary carcinomas of the ear].
  • The most common symptoms of patients with carcinomas of the middle ear or mastoid are otorrhea, facial paralysis, and hearing loss, including a sensorineural element and vertigo.
  • The latter two symptoms are indicators of inner ear damage.
  • However, few reports have been made concerning the histopathological changes that occur in the inner ear in the presence of a tumor.
  • The present study was performed to determine the pattern of tumor invasion in the inner ear and the histopathological changes that occur in the inner ear in cases of ear carcinomas.
  • Temporal bone sections from five patients (age: #39-73 years; 3 males and 2 females) who died from a primary carcinoma of the ear were studied histologically.
  • 1) localization of the tumor in the temporal bone, 2) pattern of tumor invasion in the inner ear, 3) pathological changes in the inner ear, including the cochlea, vestibule and semicircular canals.
  • Tumor cells were still present in the temporal bone sections of all the patients except one, even though the patients had received various treatments for the carcinoma, including radiation therapy, surgery and chemotherapy.
  • Marked inflammatory and necrotic changes were observed in cases where the tumor had invaded the external auditory canal, middle ear cleft, internal auditory canal, and in some cases the inner ear.
  • In cases where the tumor invaded the inner ear via the internal auditory canal rather than directly from the middle ear, the otic capsule is thought to have acted as a barrier against tumor invasion.
  • In addition, marked degenerative changes throughout the entire inner ear structures were noted.
  • These changes may have arisen from an attenuated blood supply to the inner ear as a result of pressure from the tumor in the internal auditory canal, tumor infiltration of the labyrinthine artery.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ear Neoplasms / pathology. Ear, Inner / pathology. Temporal Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109823.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


11. Chee G, Mok P, Sim R: Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis. Singapore Med J; 2000 Sep;41(9):441-6, 451
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis.
  • Squamous cell carcinoma of the external ear canal is an uncommon condition that is associated with a poor outcome.
  • The development of an accepted staging system has not been forthcoming and this has inhibited the formation of an evidence-based therapeutic protocol.
  • We report the findings in 14 patients with squamous cell carcinoma of the external ear canal treated in our institutions.
  • Four patients had a history of chronic ear discharge and one had previous radiotherapy for nasopharyngeal carcinoma.
  • With combination treatment involving surgery, radiotherapy and chemotherapy, disease free survival achieved was 69% (9 of 13) over a mean follow-up period of 24.7 months.
  • One patient absconded treatment.
  • [MeSH-major] Carcinoma, Squamous Cell. Skull Neoplasms. Temporal Bone / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193117.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


12. Rinaldo A, Devaney KO, Ferlito A: Merkel cell carcinoma of the auricle. Acta Otolaryngol; 2005 Feb;125(2):125-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the auricle.
  • Merkel cell carcinoma (MCC) is an uncommon cutaneous neoplasm which arises in adults with a peak incidence in the sixth and seventh decades.
  • The mainstay of treatment is surgery, with attempts at complete surgical excision being of paramount importance.
  • What role regional node dissection, radiation therapy and chemotherapy may play in the standard treatment of auricular MCC remains to be clearly established.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Ear, External. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880940.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 34
  •  go-up   go-down


13. Ueda Y, Kurita T, Matsuda Y, Ito S, Nakashima T: Superselective, intra-arterial, rapid infusion chemotherapy for external auditory canal carcinoma. J Laryngol Otol Suppl; 2009;(31):75-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superselective, intra-arterial, rapid infusion chemotherapy for external auditory canal carcinoma.
  • Previously, the treatment of carcinoma of the external auditory canal has mainly involved surgical resection.
  • In order to enable organ preservation and to obtain cancer-free surgical margins, we introduced the use of superselective, intra-arterial, rapid infusion chemotherapy combined with radiotherapy to treat this condition.We reviewed our patients' tumour stages, feeding arteries and clinical outcomes.
  • Chemotherapy was administered intra-arterially in the angiography suite via transfemoral catheterisation of the feeding arteries.
  • The overall toxic side effects were modest.Superselective, intra-arterial, rapid infusion chemotherapy can be an effective, organ-preserving treatment for external auditory canal carcinoma, with a high cure rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Ear Canal. Ear Neoplasms / drug therapy. Infusions, Intra-Arterial / methods
  • [MeSH-minor] Aged. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460210.001).
  • [ISSN] 0144-2945
  • [Journal-full-title] The Journal of laryngology and otology. Supplement
  • [ISO-abbreviation] J Laryngol Otol Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Linder T, Schlegel C, DeMin N, van der Westhuizen S: Active middle ear implants in patients undergoing subtotal petrosectomy: new application for the Vibrant Soundbridge device and its implication for lateral cranium base surgery. Otol Neurotol; 2009 Jan;30(1):41-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active middle ear implants in patients undergoing subtotal petrosectomy: new application for the Vibrant Soundbridge device and its implication for lateral cranium base surgery.
  • OBJECTIVE: The functional outcome of ossiculoplasties in chronic ear and lateral cranium base surgery depends on the presence of a ventilated middle ear space and is guided by the existence or absence of ossicular remnants.
  • PATIENTS AND INTERVENTION: Starting in January 2006, five patients underwent a subtotal petrosectomy to control their chronically discharging ear, to remove residual cholesteatoma, or to revise previous incompletely exenterated cavities.
  • In all operations, the external ear canal and the eustachian tube were closed, and the cavity was obliterated using abdominal fat.
  • MAIN OUTCOME MEASURES: Preoperative and postoperative pure tone audiograms were analyzed in respect to deterioration of inner ear function, aided and unaided (hearing aid, VSB, and Bone-Anchored Hearing Aid) speech audiograms were compared to verify improvements in communication skills, functional gains were calculated at comfortable level settings, and postoperative computed tomographic scans were used to exclude recurrent disease and to confirm the position of the FMT onto the round window membrane.
  • RESULTS: All patients were very satisfied daily users of their middle ear implant and had complete eradication of their middle ear pathology.
  • Bone conduction worsened at 2 kHz, with preservation of inner ear function in the other frequencies.
  • CONCLUSION: Patients with combined hearing loss undergoing subtotal petrosectomy with complete fat obliteration of the middle ear and mastoid area can be safely rehabilitated, placing the FMT of a VSB onto the round window membrane, either at the time of primary surgery, or as a staged secondary procedure.
  • [MeSH-minor] Aged. Audiometry. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cochlear Implantation / methods. Ear, External / surgery. Ear, Middle / abnormalities. Female. Granuloma / surgery. Hearing Aids. Humans. Male. Mastoid / abnormalities. Mastoiditis / diagnosis. Mastoiditis / surgery. Middle Aged. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Otologic Surgical Procedures / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849883.001).
  • [ISSN] 1537-4505
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Meyer TK, Rhee JS, Smith MM, Cruz MJ, Osipov VO, Wackym PA: External auditory canal eccrine spiradenocarcinoma: a case report and review of literature. Head Neck; 2003 Jun;25(6):505-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External auditory canal eccrine spiradenocarcinoma: a case report and review of literature.
  • BACKGROUND: Eccrine spiradenocarcinoma is a rare dermal appendage carcinoma believed to arise from transformation of a long-standing benign spiradenoma.
  • METHODS: We report the first case of eccrine spiradenocarcinoma arising in the external auditory canal.
  • Primary treatment should include wide local excision with or without regional lymphadenectomy.
  • Isolated successful treatments have been documented with adjuvant hormonal manipulation, chemotherapy, and radiation therapy.
  • [MeSH-major] Ear Canal / pathology. Ear Neoplasms / diagnosis. Neoplasms, Adnexal and Skin Appendage / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc.
  • (PMID = 12784243.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


16. Stell AJ, Dobson JM, Langmack K: Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid. J Small Anim Pract; 2001 Apr;42(4):164-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid.
  • A study was undertaken to investigate the treatment of superficial squamous cell carcinoma of the nasal planum, pinna and eyelid in cats by photodynamic therapy, using topical 5-aminolaevulinic acid cream, with subsequent exposure to red light of wavelength 635 nm, supplied by a light-emitting diode source.
  • After a single treatment, complete responses were seen in nine out of 10 nasal planum lesions, one out of two pinnal lesions and the eyelid lesion.
  • The overall complete response rate for lesions managed with a single photodynamic therapy treatment was 85 per cent.
  • Seven of the 11 lesions (63.6 per cent) showing a complete response subsequently recurred; the time to recurrence ranged from 19 to 56 weeks (median 21 weeks, mean 26.7 weeks).
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Squamous Cell / veterinary. Cat Diseases / drug therapy. Neoplasm Recurrence, Local / veterinary. Photochemotherapy / veterinary. Photosensitizing Agents / therapeutic use. Skin Neoplasms / veterinary
  • [MeSH-minor] Administration, Topical. Animals. Cats. Ear, External. Eyelid Neoplasms / drug therapy. Eyelid Neoplasms / veterinary. Light. Nose. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11327662.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


17. Lain EL, Markus RF: Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine. J Drugs Dermatol; 2004 Nov-Dec;3(6):680-2
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine.
  • We report two patients with explosive basal cell carcinoma and keratoacanthoma development, respectively, within 3 months of initiation of cyclosporine.
  • Neither patient had a history of skin cancer, had received PUVA therapy, or was on additional immunosuppressive therapy.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Cyclosporine / adverse effects. Hand Dermatoses / diagnosis. Immunosuppressive Agents / adverse effects. Keratoacanthoma / diagnosis. Psoriasis / drug therapy. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Ear, External. Female. Humans. Male. Middle Aged


18. El Sayed F, Dhaybi R, Ammoury A, El Haddad B, Bazex J: [The syndrome of bazex or acrokeratosis paraneoplastica]. J Med Liban; 2006 Jan-Mar;54(1):28-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bazex syndrome or acrokeratosis paraneoplastica is a rare dermatosis usually associated with a squamous cell carcinoma of upper aerodigestive tract or with metastases in the cervical lymph nodes.
  • Treatment consists of treating the underlying neoplasia whether by surgery, chemotherapy and/or radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Keratosis / diagnosis. Keratosis / therapy. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / therapy
  • [MeSH-minor] Ear, External / pathology. Head and Neck Neoplasms / pathology. Humans. Nails / pathology. Nose / pathology. Psoriasis. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044630.001).
  • [ISSN] 0023-9852
  • [Journal-full-title] Le Journal médical libanais. The Lebanese medical journal
  • [ISO-abbreviation] J Med Liban
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Lebanon
  • [Number-of-references] 24
  •  go-up   go-down


19. Landström FJ, Nilsson CO, Crafoord S, Reizenstein JA, Adamsson GB, Löfgren LA: Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg; 2010 Aug;36(8):1245-50
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electroporation therapy of skin cancer in the head and neck area.
  • BACKGROUND: Electroporation therapy is a new cancer treatment modality in which a locally applied electrical field enhances cell membrane permeability, allowing greater intracellular accumulation of a chemotherapeutic agent.
  • OBJECTIVE: To evaluate the efficacy of electroporation therapy in treating basal cell and squamous cell carcinomas of the skin.
  • MATERIALS AND METHODS: Six patients with skin cancer of the head and neck were treated using electroporation therapy with intratumorally injected bleomycin.
  • Orbital growth, facial nerve proximity, or proximity to cartilage of the external meatus complicated four of these tumors.
  • RESULTS: In four of the six patients, one treatment was enough to eradicate the tumor.
  • In one patient, the tumor persisted even after a second treatment with electroporation therapy.
  • One additional recurrence was recorded 6 months after the follow-up period CONCLUSION: Electroporation therapy is a promising new cancer treatment that should be further evaluated as an alternative to surgery, especially in complicated skin cancer.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Electrochemotherapy. Head and Neck Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Ear Neoplasms / drug therapy. Female. Humans. Male. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2011 Feb;37(2):286; author reply 287 [21324036.001]
  • (PMID = 20666812.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


20. Bast F, Risteska K, Jovanovic S, Sedlmaier B: [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report]. Laryngorhinootologie; 2009 Aug;88(8):528-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report].
  • Besides its use as an adjunction in the treatment of breast, lung and prostate cancer, or as a second-line cytostatic drug for head and neck squamous cell carcinoma (HNSCC), since 1963, MMC has also been successfully used in the suppression of post-operative scar formation, particularly in the field of ophthalmology.
  • In this résumé, we wish to recapitulate our long years of experience in the topical application of Mitomycin C in the treatment of scar formation and stenosis in head and neck organs.
  • The fields of application included laryngeal, tracheal, oesophageal stenosis and stenosis of the external ear canal and the choane.
  • CONCLUSION: The topical application of MMC appears to be an effective adjunction as a concept of treatment for stenosising, scar-forming lesions.
  • This topical application, however, is not a substitute for correct diagnosis and appropriate surgical treatment.
  • [MeSH-major] Airway Obstruction / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Cicatrix / drug therapy. Mitomycin / administration & dosage. Postoperative Complications / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Inspiratory Capacity / drug effects. Laryngoscopy. Laryngostenosis / diagnosis. Laryngostenosis / drug therapy. Laryngostenosis / surgery. Laser Therapy. Male. Middle Aged. Recurrence. Reoperation. Retreatment. Retrospective Studies. Tracheal Stenosis / diagnosis. Tracheal Stenosis / drug therapy. Tracheal Stenosis / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19554503.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


21. Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH, National Cancer Institute Phase 0 Working Group: Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther; 2009 Nov;8(21):2004-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
  • PURPOSE: Targeting the poly (ADP-ribose) polymerase (PARP) pathway for cancer treatment has been an active area of pre-clinical and clinical research.
  • We aimed to determine whether the PARP inhibitor ABT-888 hits its therapeutic target in tumors by immunohistochemistry during a Phase 0 trial conducted at the National Cancer Institute.
  • EXPERIMENTAL DESIGN: The expression of poly (ADP-ribose) (PAR) and full size PARP-1 were quantitatively examined by immunohistochemistry in paraffin-embedded tumor biopsies at baseline and 3-24 h after a single oral dose (25 or 50 mg) of ABT-888.
  • RESULTS: Baseline PAR levels were moderate to high in three patients with non-Hodgkin lymphomas, and one each with small cell lung cancer, squamous cell carcinoma of the tongue and melanoma; low in two patients with cutaneous T-cell lymphoma and one with adenocarcinoma of external ear canal.
  • A significant decrease in PAR (median decrease 30.2, range -13.1 to -69.8) was achieved after drug administration (n = 6 pairs; p = 0.03), whereas an increase in PARP-1 expression was observed in five of the six tumors.
  • This resulted in a decrease in the ratio of PAR to PARP-1 in tumor biopsies (median -6.76, range -0.41 to -22.59; p = 0.03).
  • CONCLUSIONS: ABT-888 hits its therapeutic target by significantly reducing PAR levels and the ratio of PAR to PARP-1 in human tumor cells detected by immunohistochemistry.
  • Baseline tumor PAR levels vary considerably among patients who entered this phase 0 study.
  • This underscores a need to investigate baseline PAR levels in association with response in future preclinical and clinical studies.
  • [MeSH-major] Benzimidazoles / pharmacology. Enzyme Inhibitors / pharmacology. Lymphoma / drug therapy. Neoplasms / drug therapy. Neoplasms / enzymology. Poly(ADP-ribose) Polymerase Inhibitors
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Poly(ADP-ribose) Polymerases / biosynthesis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(21):2010-2 [20037466.001]
  • (PMID = 19823047.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzimidazoles; 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 01O4K0631N / veliparib; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down






Advertisement